A Phase 1/2 interventional study of Regorafenib and Atezolizumab in Colorectal Cancer, sponsored by Hoffmann-La Roche. Terminated at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.
Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 22nd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2018, is one of 8 in phase 1/2, and was the 31st registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–75
National Cancer Institute, Naples · Sites in Italy
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18+
By country, each count listing its studies:
regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 39 · Phase 3 9 · Phase 4 3
First in 2009; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 55 across the 58 interventional studies. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 6 under way, none of them phase 3. Of 100 finished, 52 (52%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 39th largest by enrollment of the 77 interventional ones that give a count, is the only one that started in 2018, is one of 3 in phase 1/2, and was the 97th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
3 of the studies testing regorafenib in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06558773Chinese PLA General HospitalGSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. | 2027-03-01 |
| NCT06425133Centre Hospitalier Universitaire de BesanconRegorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers | 2027-09 |
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies testing regorafenib in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Drug: Regorafenib
Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
Drug: Atezolizumab · Drug: Imprime PGG · Drug: Bevacizumab
Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
Drug: Atezolizumab · Drug: Isatuximab
Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
Drug: Atezolizumab · Drug: Bevacizumab · Drug: Selicrelumab
Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
Drug: Atezolizumab · Drug: Idasanutlin
Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
Drug: Regorafenib · Drug: Atezolizumab
Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
Drug: Regorafenib · Drug: Atezolizumab · Drug: AB928
Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
Drug: Atezolizumab · Genetic: LOAd703
Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
Also known as: Delolimogene mupadenorepvec
Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
The best confirmed overall response rate (ORR) is defined as the percentage of participants with a complete response or partial response on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to RECIST v1.1. Participants could be classified as "Stable Disease" if the assessment was at least 6 weeks from randomization. Participants were classified as Missing if no post-baseline response assessments were available. Participants were classified as Not Evaluable if all post-baseline response assessments were unevaluable. The differences in ORR between the experimental arms and the corresponding control arm were calculated, along with 95% confidence intervals (CIs), using normal approximation of the binomial distribution. The 95% CIs for ORRs were constructed using the Clopper-Pearson method. The 95% CIs for the difference in rates were constructed using the Wald method with continuity correction.
Time frame: From randomization until disease progression or loss of clinical benefit (up to 4 years)
Progression-Free Survival (PFS) as Determined by Investigator According to RECIST v1.1
Progression-free survival (PFS) after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), was determined by the investigator according to RECIST v1.1. For participants who did not have documented disease progression or death, PFS was censored at the day of the last tumor assessment. The Kaplan-Meier method was used to estimate the median for PFS with 95% confidence intervals (CIs) constructed through use of the Brookmeyer and Crowley method.
Time frame: From randomization up to the first occurrence of disease or death from any cause (up to 4 years)
Overall Survival (OS)
Overall survival (OS) is defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. The Kaplan-Meier method was used to estimate the median for OS with 95% confidence intervals (CIs) constructed through use of the Brookmeyer and Crowley method.
Time frame: From randomization up to death from any cause (up to 4 years)
Percentage of Participants Who Were Alive at Landmark Timepoints for Overall Survival (OS)
Overall survival (OS) is defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. OS is shown as the percentage of participants who were event-free at the landmark timepoints of 3, 6, 12, and 18 months.
Time frame: 3, 6, 12, and 18 months
Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1
Duration of response is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause.
Time frame: From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 4 years)
Disease Control Rate (DCR), as Determined by the Investigator Per RECIST v1.1
Disease control rate is defined as the percentage of participants with stable disease for ≥12 weeks or a complete or partial response, as determined by the investigator according to RECIST v1.1.
Time frame: From randomization until disease progression or loss of clinical benefit (up to 4 years)
Percentage of Participants With at Least One Adverse Event (AE)
The incidence, nature, and severity of adverse events (AEs) are reported, with severity determined according to NCI CTCAE v4.0. All AEs were reported until 30 days after the last study dose or until start of new systemic anti-cancer therapy. Serious AEs and AEs of special interest were reported until 135 days (or 180 days for the Atezolizumab + LOAd703 arm only) after the last dose of study treatment.
Time frame: Adverse event data were collected from baseline up to 6 months after the last dose of study treatment (up to 640 days); deaths (all-cause) were reported from baseline through survival follow-up (up to 4 years)
The study was conducted at 15 centers in 5 countries: United States, France, Republic of Korea, Australia, and Switzerland.
| Milestone | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| Started | 24 | 15 | 15 | 6 | 4 | 15 | 15 | 2 |
| Received at least one dose of study treatment | 19 | 15 | 15 | 6 | 4 | 15 | 15 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 24 | 15 | 15 | 6 | 4 | 15 | 15 | 2 |
| Withdrew: Death | 18 | 15 | 15 | 4 | 4 | 11 | 12 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 | 2 | 0 | 1 | 0 | 0 |
The best confirmed overall response rate (ORR) is defined as the percentage of participants with a complete response or partial response on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to RECIST v1.1. Participants could be classified as "Stable Disease" if the assessment was at least 6 weeks from randomization. Participants were classified as Missing if no post-baseline response assessments were available. Participants were classified as Not Evaluable if all post-baseline response assessments were unevaluable. The differences in ORR between the experimental arms and the corresponding control arm were calculated, along with 95% confidence intervals (CIs), using normal approximation of the binomial distribution. The 95% CIs for ORRs were constructed using the Clopper-Pearson method. The 95% CIs for the difference in rates were constructed using the Wald method with continuity correction.
| Percentage of Participants | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| Responders (CR + PR) | 0 (0 to 17.65) | 0 (0 to 21.80) | 0 (0 to 21.80) | 0 (0 to 45.93) | 0 (0 to 60.24) | 6.7 (0.17 to 31.95) | 6.7 (0.17 to 31.95) | 0 (0 to 84.19) |
| Complete Response (CR) | 0 (0 to 17.65) | 0 (0 to 21.80) | 0 (0 to 21.80) | 0 (0 to 45.93) | 0 (0 to 60.24) | 0 (0 to 21.80) | 0 (0 to 21.80) | 0 (0 to 84.19) |
| Partial Response (PR) | 0 (0 to 17.65) | 0 (0 to 21.80) | 0 (0 to 21.80) | 0 (0 to 45.93) | 0 (0 to 60.24) | 6.7 (0.17 to 31.95) | 6.7 (0.17 to 31.95) | 0 (0 to 84.19) |
| Stable Disease (SD) | 63.2 (38.36 to 83.71) | 33.3 (11.82 to 61.62) | 20.0 (4.33 to 48.09) | 50 (11.81 to 88.19) | 0 (0 to 60.24) | 33.3 (11.82 to 61.62) | 53.3 (26.59 to 78.73) | 0 (0 to 84.19) |
| Progressive Disease (PD) | 26.3 (9.15 to 51.20) | 66.7 (38.38 to 88.18) | 66.7 (38.38 to 88.18) | 33.3 (4.33 to 77.72) | 100 (39.76 to 100) | 46.7 (21.27 to 73.41) | 26.7 (7.79 to 55.10) | 100 (15.81 to 100) |
| Not Evaluable | 0 (NA to NA) | 0 (NA to NA) | 13.3 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 13.3 (NA to NA) | 0 (NA to NA) |
| Missing | 10.5 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 16.7 (NA to NA) | 0 (NA to NA) | 13.3 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) |
Progression-free survival (PFS) after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), was determined by the investigator according to RECIST v1.1. For participants who did not have documented disease progression or death, PFS was censored at the day of the last tumor assessment. The Kaplan-Meier method was used to estimate the median for PFS with 95% confidence intervals (CIs) constructed through use of the Brookmeyer and Crowley method.
| Months | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) as Determined by Investigator According to RECIST v1.1 | 2.83 (2.20 to 3.02) | 1.51 (1.38 to 2.79) | 1.41 (1.41 to 1.77) | 4.21 (1.68 to NA) | 1.26 (0.82 to NA) | 1.81 (1.38 to 2.96) | 4.60 (2.60 to 5.78) | 1.58 (1.51 to NA) |
Overall survival (OS) is defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. The Kaplan-Meier method was used to estimate the median for OS with 95% confidence intervals (CIs) constructed through use of the Brookmeyer and Crowley method.
| Months | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 10.15 (4.40 to 12.29) | 5.72 (4.37 to 10.51) | 5.13 (3.12 to 7.75) | 14.36 (3.22 to NA) | 5.93 (1.61 to NA) | 11.01 (5.29 to 16.66) | 8.67 (6.60 to 14.62) | 4.07 (NA to NA) |
Overall survival (OS) is defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. OS is shown as the percentage of participants who were event-free at the landmark timepoints of 3, 6, 12, and 18 months.
| Percentage of Participants | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| 3 Months | 84.21 (67.81 to 100) | 100.00 (100.00 to 100.00) | 73.33 (50.95 to 95.71) | 100.00 (100.00 to 100.00) | 75.00 (32.57 to 100.00) | 78.97 (57.78 to 100.00) | 86.67 (69.46 to 100.00) | 100.00 (100.00 to 100.00) |
| 6 Months | 63.16 (41.47 to 84.85) | 46.67 (21.42 to 71.91) | 40.00 (15.21 to 64.79) | 80.00 (44.94 to 100.00) | 50.00 (1.00 to 99.00) | 71.79 (48.32 to 95.27) | 73.33 (50.95 to 95.71) | — |
| 12 Months | 34.45 (12.42 to 56.48) | 20.00 (0.00 to 40.24) | 26.67 (4.29 to 49.05) | 53.33 (4.68 to 100) | 25.00 (0.00 to 67.43) | 39.89 (13.18 to 66.59) | 33.33 (9.48 to 57.19) | — |
| 18 Months | 17.22 (0.00 to 34.87) | 6.67 (0.00 to 19.29) | 20.00 (0.00 to 40.24) | 26.67 (0.00 to 70.97) | 25.00 (0.00 to 67.43) | 23.93 (0.48 to 47.39) | 26.67 (4.29 to 49.05) | — |
Duration of response is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause.
| Months | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1 | — | — | — | — | — | 3.12 (NA to NA) | 5.75 (NA to NA) | — |
Disease control rate is defined as the percentage of participants with stable disease for ≥12 weeks or a complete or partial response, as determined by the investigator according to RECIST v1.1.
| Percentage of Participants | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR), as Determined by the Investigator Per RECIST v1.1 | 15.8 (3.38 to 39.58) | 13.3 (1.66 to 40.46) | 6.7 (0.17 to 31.95) | 33.3 (4.33 to 77.72) | 0 (0.00 to 60.24) | 13.3 (1.66 to 40.46) | 40.0 (16.34 to 67.71) | 0 (0.00 to 84.19) |
The incidence, nature, and severity of adverse events (AEs) are reported, with severity determined according to NCI CTCAE v4.0. All AEs were reported until 30 days after the last study dose or until start of new systemic anti-cancer therapy. Serious AEs and AEs of special interest were reported until 135 days (or 180 days for the Atezolizumab + LOAd703 arm only) after the last dose of study treatment.
| Percentage of Participants | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| Adverse Event (AE) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Death | 89.5 | 100 | 100 | 66.7 | 100 | 73.3 | 80.0 | 50.0 |
| Withdrawn from Stage due to an AE | 15.8 | 6.7 | 0 | 0 | 0 | 6.7 | 6.7 | 0 |
| AE with a Fatal Outcome | 10.5 | 0 | 0 | 0 | 0 | 6.7 | 0 | 0 |
| Serious AE (SAE) | 26.3 | 6.7 | 33.3 | 50.0 | 25.0 | 46.7 | 46.7 | 50.0 |
| SAE Leading to Withdrawal from any Treatment | 21.1 | 6.7 | 0 | 0 | 0 | 6.7 | 0 | 0 |
| SAE Leading to Dose Modification/Interruption | 5.3 | 0 | 6.7 | 50.0 | 0 | 26.7 | 46.7 | 0 |
| Related SAE | 5.3 | 6.7 | 0 | 50.0 | 25.0 | 26.7 | 33.3 | 50.0 |
| AE Leading to Withdrawal from any Treatment | 26.3 | 6.7 | 0 | 0 | 0 | 20.0 | 6.7 | 0 |
| AE Leading to Dose Modification/Interruption | 63.2 | 40.0 | 13.3 | 50.0 | 75.0 | 86.7 | 93.3 | 0 |
| Related AE | 94.7 | 86.7 | 86.7 | 100 | 100 | 93.3 | 100 | 50.0 |
| Related AE Leading to Withdrawal from any Treatment | 10.5 | 6.7 | 0 | 0 | 0 | 6.7 | 6.7 | 0 |
| Related AE Leading to Dose Modification/Interruption | 47.4 | 33.3 | 0 | 33.3 | 75.0 | 73.3 | 93.3 | 0 |
| Grade 3-5 AE | 68.4 | 20.0 | 46.7 | 50.0 | 75.0 | 66.7 | 60.0 | 0 |
| Worst Grade AE: 5 | 10.5 | 0 | 0 | 0 | 0 | 6.7 | 0 | 0 |
| Worst Grade AE: 4 | 5.3 | 0 | 6.7 | 0 | 25.0 | 6.7 | 13.3 | 0 |
| Worst Grade AE: 3 | 52.6 | 20.0 | 40.0 | 50.0 | 50.0 | 53.3 | 46.7 | 0 |
Collected over Adverse event data were collected from first study dose up to 6 months after the last dose of study treatment (up to 640 days); deaths (all-cause) were reported from enrolment through survival follow-up (up to 4 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regorafenib (Control) | 18/24 (75%) | 5/19 (26.3%) | 19/19 (100%) |
| Atezolizumab + Imprime PGG + Bevacizumab | 15/15 (100%) | 1/15 (6.7%) | 15/15 (100%) |
| Atezolizumab + Isatuximab | 15/15 (100%) | 5/15 (33.3%) | 15/15 (100%) |
| Atezolizumab + Selicrelumab + Bevacizumab | 4/6 (66.7%) | 3/6 (50%) | 6/6 (100%) |
| Atezolizumab + Idasanutlin | 4/4 (100%) | 1/4 (25%) | 4/4 (100%) |
| Atezolizumab + Regorafenib | 11/15 (73.3%) | 7/15 (46.7%) | 15/15 (100%) |
| Atezolizumab + Regorafenib + AB928 | 12/15 (80%) | 7/15 (46.7%) | 15/15 (100%) |
| Atezolizumab + LOAd703 | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Event | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| Cytokine release syndromeImmune system disorders | 0/19 | 0/15 | 0/15 | 0/6 | 0/4 | 0/15 | 0/15 | 1/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/19 | 0/15 | 0/15 | 0/6 | 1/4 | 0/15 | 0/15 | 0/2 |
| PyrexiaGeneral disorders | 0/19 | 0/15 | 0/15 | 0/6 | 0/4 | 3/15 | 2/15 | 0/2 |
| Atrial flutterCardiac disorders | 0/19 | 0/15 | 0/15 | 1/6 | 0/4 | 0/15 | 0/15 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 0/15 | 0/15 | 1/6 | 0/4 | 0/15 | 0/15 | 0/2 |
| Small intestinal obstructionGastrointestinal disorders | 0/19 | 0/15 | 1/15 | 1/6 | 0/4 | 0/15 | 0/15 | 0/2 |
| VomitingGastrointestinal disorders | 1/19 | 0/15 | 0/15 | 1/6 | 0/4 | 0/15 | 0/15 | 0/2 |
| SyncopeNervous system disorders | 0/19 | 0/15 | 0/15 | 1/6 | 0/4 | 0/15 | 0/15 | 0/2 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/19 | 0/15 | 0/15 | 1/6 | 0/4 | 0/15 | 0/15 | 0/2 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/19 | 0/15 | 1/15 | 1/6 | 0/4 | 0/15 | 0/15 | 0/2 |
| Event | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 7/19 | 3/15 | 6/15 | 0/6 | 4/4 | 3/15 | 2/15 | 1/2 |
| VomitingGastrointestinal disorders | 1/19 | 4/15 | 3/15 | 1/6 | 4/4 | 3/15 | 2/15 | 0/2 |
| FatigueGeneral disorders | 8/19 | 7/15 | 9/15 | 2/6 | 1/4 | 7/15 | 4/15 | 2/2 |
| Injection site reactionGeneral disorders | 0/19 | 0/15 | 0/15 | 5/6 | 0/4 | 0/15 | 0/15 | 0/2 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/19 | 8/15 | 11/15 | 0/6 | 0/4 | 2/15 | 4/15 | 0/2 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 12/19 | 0/15 | 0/15 | 0/6 | 0/4 | 5/15 | 4/15 | 0/2 |
| Abdominal distensionGastrointestinal disorders | 0/19 | 0/15 | 1/15 | 0/6 | 1/4 | 1/15 | 0/15 | 1/2 |
| Abdominal painGastrointestinal disorders | 5/19 | 3/15 | 4/15 | 0/6 | 1/4 | 1/15 | 4/15 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 6/19 | 6/15 | 2/15 | 2/6 | 2/4 | 7/15 | 4/15 | 0/2 |
| Cytokine release syndromeImmune system disorders | 0/19 | 0/15 | 0/15 | 0/6 | 0/4 | 0/15 | 0/15 | 1/2 |
All participants who were randomized in the study, regardless of whether they actually received any study treatment.
| Age, Continuous(Years) | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age (year) | 59.5 ± 10.3 | 57.8 ± 5.9 | 52.3 ± 12.0 | 66.8 ± 10.0 | 56.3 ± 6.8 | 56.4 ± 8.2 | 55.1 ± 9.2 | 58.0 ± 11.3 | 57.2 ± 9.7 |
| Sex: Female, Male(Participants) | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 12 | 7 | 6 | 1 | 3 | 11 | 4 | 1 | 45 |
| Male | 12 | 8 | 9 | 5 | 1 | 4 | 11 | 1 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 3 | 1 | 0 | 1 | 0 | 1 | 12 |
| Not Hispanic or Latino | 21 | 10 | 11 | 4 | 4 | 11 | 14 | 1 | 76 |
| Unknown or Not Reported | 1 | 1 | 1 | 1 | 0 | 3 | 1 | 0 | 8 |
| Race (NIH/OMB)(Participants) | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 7 | 6 | 4 | 0 | 1 | 5 | 8 | 0 | 31 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| White | 15 | 7 | 10 | 5 | 3 | 7 | 6 | 2 | 55 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 | 1 | 0 | 2 | 1 | 0 | 6 |
| ECOG score(Participants) | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 | Total |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11 | 8 | 5 | 5 | 1 | 7 | 7 | 1 | 45 |
| 1 | 13 | 7 | 10 | 1 | 3 | 8 | 8 | 1 | 51 |
| Number of Metastatic Sites at Enrollment(Participants) | Regorafenib (Control) | Atezolizumab + Imprime PGG + Bevacizumab | Atezolizumab + Isatuximab | Atezolizumab + Selicrelumab + Bevacizumab | Atezolizumab + Idasanutlin | Atezolizumab + Regorafenib | Atezolizumab + Regorafenib + AB928 | Atezolizumab + LOAd703 | Total |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 6 |
| 2 | 4 | 5 | 3 | 3 | 3 | 7 | 5 | 0 | 30 |
| 3 | 9 | 5 | 8 | 0 | 0 | 2 | 6 | 2 | 32 |
| >=4 | 8 | 4 | 4 | 3 | 1 | 5 | 3 | 0 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Sep 2022, 47 months.
Results were first posted in Nov 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Regorafenib · BTH1677 · Bevacizumab · Isatuximab · Selicrelumab · RG7388 · AB928